Improved Aseptic Processes and Monitoring to Reduce FDA 483s

In recent years, the FDA response to companies with insufficient proof of control over their production has become more aggressive, demonstrated by the rise in 483s and warning letters issued. Topics related to environmental monitoring programs are included in the most common reasons 483s are issued. By becoming aware of the regulations and reasoning backing 483 distribution, pharmaceutical companies prepare against making mistakes.

Interested in learning more? Complete the form on this page to receive a free copy of Improved Aseptic Processes and Monitoring to Reduce FDA 483s.